
​
Accelerating Health Cures, Therapies and Intelligence
AMBITNA PaSCLTM
Medical Research Accelerator
Accelerating bringing new therapies to market faster by automatically matching a more diverse, eligible patients to trials and clinical sites

Access
Only 4-8% of ELIGIBLE patients ACCESS clinical research
​
AMBITNA automatically and securely connects eligible patients with their providers to researchers for faster discovery of cures with security, privacy, and distributed analytics.
​
Patients and their providers automatically know what is accessible to accelerate a cure and extend a life.
HEALTH EQUITY
With AMBITNA, a more diverse population can participate in clinical research.
Presently, minorities and women are under-represented in clinical trials. This represents a delay to the approval of drugs, understanding of all side effects and true dosing. It also increases the chances that after approval, the number of side effects, complications and dosing issues create a major liability burden for the pharmaceutical and the health care system involved.
SECURITY
AMBITNA uses military-grade security to protect patient and clinical trial data at rest and in motion with a technology fabric that does not require data to be centrally stored to provide the AI to securely connect patients and providers to clinical trials.
SAVINGS
AMBITNA saves time and money to identify and enroll eligible patients in research.
Pharma can accelerate the regulatory approval process; increase the cohort of patient pools with more diversity on gender, race, ethnicity and age thus decreasing liability; and increase ROI while mitigating product liability.
Improving health outcomes faster saves both the patient and payor.